ATE384800T1 - Multifunktionelle protease-inhibitoren und deren verwendung zur behandlung von krankheiten - Google Patents

Multifunktionelle protease-inhibitoren und deren verwendung zur behandlung von krankheiten

Info

Publication number
ATE384800T1
ATE384800T1 AT01988344T AT01988344T ATE384800T1 AT E384800 T1 ATE384800 T1 AT E384800T1 AT 01988344 T AT01988344 T AT 01988344T AT 01988344 T AT01988344 T AT 01988344T AT E384800 T1 ATE384800 T1 AT E384800T1
Authority
AT
Austria
Prior art keywords
fusion proteins
treatment
protease
protease inhibitors
diseases
Prior art date
Application number
AT01988344T
Other languages
English (en)
Inventor
Philip Barr
Helen Gibson
Philip Pemberton
Original Assignee
Arriva Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arriva Pharmaceuticals Inc filed Critical Arriva Pharmaceuticals Inc
Application granted granted Critical
Publication of ATE384800T1 publication Critical patent/ATE384800T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/8146—Metalloprotease (E.C. 3.4.24) inhibitors, e.g. tissue inhibitor of metallo proteinase, TIMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8121—Serpins
    • C07K14/8125—Alpha-1-antitrypsin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT01988344T 2000-12-18 2001-12-18 Multifunktionelle protease-inhibitoren und deren verwendung zur behandlung von krankheiten ATE384800T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25669900P 2000-12-18 2000-12-18
US33196601P 2001-11-20 2001-11-20

Publications (1)

Publication Number Publication Date
ATE384800T1 true ATE384800T1 (de) 2008-02-15

Family

ID=26945535

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01988344T ATE384800T1 (de) 2000-12-18 2001-12-18 Multifunktionelle protease-inhibitoren und deren verwendung zur behandlung von krankheiten

Country Status (7)

Country Link
EP (1) EP1366175B1 (de)
JP (2) JP4426179B2 (de)
AT (1) ATE384800T1 (de)
AU (2) AU2002241661B2 (de)
CA (1) CA2430973A1 (de)
DE (1) DE60132632T2 (de)
WO (1) WO2002050287A2 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004052236A2 (en) * 2002-12-06 2004-06-24 Arriva Pharmaceuticals, Inc. Methods and compositions for treatment of otitis media
US20070098635A1 (en) * 2003-04-08 2007-05-03 Genova Ltd. Secreted polypeptide species associatedwith cardiovascular disorders
US7419801B2 (en) 2003-08-08 2008-09-02 Arriva Pharmaceuticals, Inc. Methods of protein production in yeast
SE0302559D0 (sv) 2003-09-25 2003-09-25 Astrazeneca Ab Method
CA2559062A1 (en) 2004-03-09 2005-09-22 Arriva Pharmaceuticals, Inc. Treatment of chronic obstructive pulmonary disease by low dose inhalation of protease inhibitor
JP2007037434A (ja) * 2005-08-02 2007-02-15 Yamaguchi Univ 膵β細胞特異的に発現される人工タンパク質、該タンパク質をコードしたレポーター遺伝子及び膵β細胞量の計測方法
US8367615B2 (en) 2006-03-30 2013-02-05 Research Foundation Of City University Of New York Stimulation of neuron regeneration by secretory leukocyte protease inhibitor
EP2341138B1 (de) * 2008-10-09 2017-11-22 Oriental Yeast Co., Ltd. FUSIONSPROTEIN AUS EINEM MATRIXMETALLOPROTEINASE-2-HEMMER-PEPTID AUS EINEM AMYLIOD-ß-VORLÄUFERPROTEIN UND GEWEBEHEMMER DER METALLOPROTEINASE-2
ES2535704T3 (es) 2010-09-14 2015-05-14 F. Hoffmann-La Roche Ag Polipéptido de fusión serpina-dedo
US10400029B2 (en) 2011-06-28 2019-09-03 Inhibrx, Lp Serpin fusion polypeptides and methods of use thereof
PL2726092T3 (pl) * 2011-06-28 2019-11-29 Inhibrx Lp Polipeptydy fuzyjne serpiny i sposoby ich stosowania
SG10201610913PA (en) 2011-12-30 2017-02-27 Grifols Sa Alpha1-proteinase inhibitor for delaying the onset or progression of pulmonary exacerbations
WO2014179408A1 (en) * 2013-04-30 2014-11-06 The Trustees Of Columbia University In The City Of New York Analyzing elastic fiber injury markers
JP2016536343A (ja) * 2013-09-18 2016-11-24 ジェームス・クック・ユニバーシティー 抗炎症性のタンパク質及び使用方法
JP2016532456A (ja) 2013-09-18 2016-10-20 ジェームス・クック・ユニバーシティー 改変型抗炎症性タンパク質及び使用方法
IT202000012370A1 (it) * 2020-05-26 2021-11-26 Drugs Minerals And Generics Italia S R L In Forma Abbreviata D M G Italia S R L Composizione comprendente pepstatina e acido alginico o un suo sale e suo uso
JP2023547728A (ja) * 2020-11-06 2023-11-13 アーテック メディカル ジーエムビーエイチ 間葉系幹細胞由来の細胞外小胞およびアルファ－１アンチトリプシンを含むウイルス感染症治療用組成物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5900400A (en) * 1984-12-06 1999-05-04 Amgen Inc. Serine protease inhibitor analogs
DE3709255A1 (de) * 1987-03-20 1988-09-29 Hoechst Ag Hybridserpine und dafuer kodierende dna
US5633227A (en) * 1994-09-12 1997-05-27 Miles, Inc. Secretory leukocyte protease inhibitor as an inhibitor of tryptase
JP2001525669A (ja) * 1997-05-12 2001-12-11 ネーデルランセ オルハニサチエ フォール トゥーヘパスト−ナツールウェーテンシャッペルック オンデルズク テーエヌオー 細胞遊走の阻害のための方法および構築物
AU1101501A (en) * 1999-10-27 2001-05-08 K-Quay Enterprises, Llc Methods and compositions for treatment of keratoconus using protease inhibitors

Also Published As

Publication number Publication date
DE60132632D1 (de) 2008-03-13
WO2002050287A2 (en) 2002-06-27
EP1366175B1 (de) 2008-01-23
JP2009297031A (ja) 2009-12-24
JP2004537970A (ja) 2004-12-24
EP1366175A2 (de) 2003-12-03
CA2430973A1 (en) 2002-06-27
AU2002241661B2 (en) 2007-05-31
DE60132632T2 (de) 2009-01-22
WO2002050287A3 (en) 2003-09-18
JP4426179B2 (ja) 2010-03-03
AU4166102A (en) 2002-07-01

Similar Documents

Publication Publication Date Title
DE60132632D1 (de) Multifunktionelle protease-inhibitoren und deren verwendung zur behandlung von krankheiten
Amour et al. The enzymatic activity of ADAM8 and ADAM9 is not regulated by TIMPs
NO923469L (no) Chymotrypsin-lignende proteaser og deres inhibitorer
HUP9902698A2 (hu) Humán bikunin
ATE364698T1 (de) Neues, physiologisch aktives peptid und dessen verwendung
ATE266723T1 (de) Lösung die chaotropische mittel enthält und verwendung dieser lösung in verfahren zur isolierung von dna, rna und proteinen
DE69132352D1 (de) Protein-antagonisten der blut-koagulation und ihre verwendung
ATE362928T1 (de) 2-(1h-indazol-6-ylamino)- benzamid-verbindungen als protein kinase inhibitoren und deren verwendung zur behandlung von ophthalmischen krankheiten
DE60218179D1 (de) Peptide zur behandlung von tumoren und anderen bedingungen die die entfernung oder zerstörung von zelle erfordern
ATE209684T1 (de) Dna-sequenzen für matrix-metallproteasen, ihre herstellung und verwendung
DE3587875D1 (de) Rekombinantverfahren zur herstellung von serinproteaseinhibitoren, sowie dns-sequenzen dazu.
WO1996035788A3 (en) Kunitz type protease inhibitors
ATE385807T1 (de) Pharmazeutische verbindung und methoden zur behandlung von menschlichen karzinomen mittels arginin entzug
WO2002022662A3 (en) Insect inhibitory bacillus thuringiensis proteins, fusions, and methods of use therefor
DE69935078D1 (de) Eine mutante phospholamban moleküle und deren verwendung zur behandlung von herzkrankheiten und herzversagen
WO2002010357A3 (en) Gsk3 polypeptides
DK0458937T3 (da) Varianter af PAI-2
DE69510356D1 (de) Anti-sickling beta-globin,zusammensetzung und verfahren zur behandlung von sichelzellanämie
ATE361914T1 (de) Cathepsincysteinproteaseinhibitoren und deren verwendung zur behandlung von entzündungen und immunerkrankungen
Konttinen et al. Substrate specificity and activation mechanisms of collagenase from human rheumatoid synovium
ATE513033T1 (de) Expression von proteinen in aus nabelschnurblut gewonnenen endothelzellen
EP1497326A4 (de) Prothrombin aktivierendes protein
ATE251904T1 (de) Verwendung von bronopol zur behandlung von krankheiten beim fisch
ATE452984T1 (de) Verfahren und zusammensetzungen zur extraktion von proteinen aus zellen
DE60123109D1 (de) Mit schizophrenie in zusammenhang stehendes gen, das für ein potential-abhängiges ionkanal kodiert

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties